Abstract: In a wireless communication method, base stations having an identical number of channels for receiving narrowband modulation (UNB) are divided into groups. Data transmission channels of all base stations have identical time and frequency characteristics. All subscribers split into groups are periodically sent messages with subscriber group numbers by all the base stations. When a group number of a corresponding subscriber coincides with a group number in a message received by the subscriber, all the subscribers of the group send response messages to the base stations using UNB, wherein response messages are sent sequentially from all subgroups of subscribers of the group, and subscribers of a subgroup send response messages on different frequencies. The base stations receive the response messages on all frequencies corresponding to subscribers, decode the messages and generate a database of response messages, which can be used for generating subsequent messages with corresponding subscriber group numbers.

Abstract: In a wireless communication method, base stations having an identical number of channels for receiving narrowband modulation (UNB) are divided into groups. Data transmission channels of all base stations have identical time and frequency characteristics. All subscribers split into groups are periodically sent messages with subscriber group numbers by all the base stations. When a group number of a corresponding subscriber coincides with a group number in a message received by the subscriber, all the subscribers of the group send response messages to the base stations using UNB, wherein response messages are sent sequentially from all subgroups of subscribers of the group, and subscribers of a subgroup send response messages on different frequencies. The base stations receive the response messages on all frequencies corresponding to subscribers, decode the messages and generate a database of response messages, which can be used for generating subsequent messages with corresponding subscriber group numbers.

Abstract: Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and or 5-HT1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.

Abstract: Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and or 5-HT1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.

Abstract: Provided herein are substituted indolo[4,3-fg]quinolines of Formula (I) and (II) where R1-R6 and R13 are as defined in the specification and pharmaceutical compositions thereof which are useful in treating, preventing, or ameliorating a variety of medical disorders such as, for example, migraine. In other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and or 5-HT1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.

Abstract: Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and or 5-HT1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.